Public and HCP trust in UK pharma industry maintained 7 Sep 2023
The third annual Pharma Reputation Index, commissioned by the Association of the British Pharmaceutical Industry (ABPI), has found that the public looks favourably on the industry and continues to recognise its commitment to developing new medicines.
This year, 71% of those surveyed agreed that the sector produced effective medicines and vaccines, and employed highly skilled staff, up from 69% in 2022. However, people voiced concerns about cost pressures limiting access to new medicines.
HCPs also expressed support for pharma’s dedication to innovation, research, and adherence to ethical, quality, and safety standards. A total of 80% believed companies invested in high quality research using innovative technology.
Meanwhile, though there had been an improvement in perceptions of pricing fairness over the long term, the results showed that challenges remained regarding concerns of profit-driven motives and the need for increased transparency. This means the industry must focus more on effective communication and clarity in the future.
Read the full report here.
For help communicating the value of your new product to stakeholders and through to launch, contact PMC via firstname.lastname@example.org or T: +44 (0) 208 168 1668.